321: Summit's upcoming cancer results, Recursion's mixed data, and the next big obesity target
The Readout Loud
00:00
Mixed Results from AI-Driven Drug Development
This chapter discusses the recent mixed results from Recursion's AI-derived drug candidate for cerebral cavernous malformation, emphasizing its safety but raising concerns about its efficacy due to sparse data. The conversation also touches on the expectations for future drug candidates developed using advanced machine learning and AI techniques.
Transcript
Play full episode
